Clinical trial
Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED)
NCT00441012 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00441012 |
|---|---|
| Title | Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED) |
| Official title | A Study in Healthy Infants of the Safety, Tolerability, and Immunogenicity of Haemophilus Influenzae, Type b/Hepatitis B Vaccine Manufactured With a Modified Process |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Haemophilus Influenzae Type B, Hepatitis B |
| Intervention type | Biological |
| Interventions | Comparator: Modified Process Vaccine, Comparator: COMVAX™ |
| Enrollment | 546 |
| Start date | Dec 1, 2006 |
| Primary completion | Jun 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Feb 27, 2007 |
| Last update posted | Mar 19, 2015 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: